LIDDS
0.11
SEK
0 %
LIDDS
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
0%
-31.25%
-17.91%
-25.17%
+1.85%
-24.4%
-98.91%
-99.24%
-98.85%
liddspharma.com/en/investors
LIDDS is a pharmaceutical company. The company develops pharmaceutical products based on a patent-protected and clinically tested drug delivery technology. The properties of the products form the basis of LIDDS 'technology platform for the development of injectable drug products. LIDDS is the abbreviation for Local Intelligent Drug Delivery System and the company is headquartered in Uppsala.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
LIDDS
Daily low / high price
0.11 / 0.11
SEK
Market cap
15.01M SEK
Turnover
1.1K SEK
Volume
10K
Financial calendar
Annual report
20.02.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Daniel Lifveredson via bolag | 20.5 % | 20.5 % |
| Avanza Pension | 7.9 % | 7.9 % |
| Ove Högberg | 6.3 % | 6.3 % |
| Marita Högberg | 5.0 % | 5.0 % |
| Stefan Rehnmark | 4.9 % | 4.9 % |
| Wikow Venture | 4.5 % | 4.5 % |
| Torbjörn Browall, incl company-owned shares | 3.5 % | 3.5 % |
| Nordnet Pensionsförsäkring AB | 3.2 % | 3.2 % |
| Skyshire AB | 2.3 % | 2.3 % |
| Anders Bjartell | 1.9 % | 1.9 % |
ShowingAll content types
LIDDS AB (publ) Interim Report January – September 2024
LIDDS has decided to concentrate its activities on three project areas
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools